1. Home
  2. CAN vs GLUE Comparison

CAN vs GLUE Comparison

Compare CAN & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAN
  • GLUE
  • Stock Information
  • Founded
  • CAN 2013
  • GLUE 2019
  • Country
  • CAN Singapore
  • GLUE United States
  • Employees
  • CAN N/A
  • GLUE N/A
  • Industry
  • CAN Semiconductors
  • GLUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CAN Technology
  • GLUE Health Care
  • Exchange
  • CAN Nasdaq
  • GLUE Nasdaq
  • Market Cap
  • CAN 330.5M
  • GLUE 351.2M
  • IPO Year
  • CAN 2019
  • GLUE 2021
  • Fundamental
  • Price
  • CAN $0.78
  • GLUE $4.83
  • Analyst Decision
  • CAN Strong Buy
  • GLUE Buy
  • Analyst Count
  • CAN 6
  • GLUE 2
  • Target Price
  • CAN $2.50
  • GLUE $13.50
  • AVG Volume (30 Days)
  • CAN 34.8M
  • GLUE 376.6K
  • Earning Date
  • CAN 08-14-2025
  • GLUE 08-07-2025
  • Dividend Yield
  • CAN N/A
  • GLUE N/A
  • EPS Growth
  • CAN N/A
  • GLUE N/A
  • EPS
  • CAN N/A
  • GLUE 0.29
  • Revenue
  • CAN $345,360,000.00
  • GLUE $177,986,000.00
  • Revenue This Year
  • CAN $115.67
  • GLUE $83.76
  • Revenue Next Year
  • CAN $63.75
  • GLUE N/A
  • P/E Ratio
  • CAN N/A
  • GLUE $15.87
  • Revenue Growth
  • CAN 82.40
  • GLUE 2990.57
  • 52 Week Low
  • CAN $0.53
  • GLUE $3.50
  • 52 Week High
  • CAN $3.27
  • GLUE $12.40
  • Technical
  • Relative Strength Index (RSI)
  • CAN 55.55
  • GLUE 52.36
  • Support Level
  • CAN $0.64
  • GLUE $4.54
  • Resistance Level
  • CAN $0.77
  • GLUE $4.92
  • Average True Range (ATR)
  • CAN 0.05
  • GLUE 0.21
  • MACD
  • CAN 0.01
  • GLUE 0.05
  • Stochastic Oscillator
  • CAN 78.14
  • GLUE 88.24

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: